Chicago Capital LLC Raises Position in Danaher Co. (NYSE:DHR)

Chicago Capital LLC lifted its stake in shares of Danaher Co. (NYSE:DHR) by 16.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,887 shares of the conglomerate’s stock after buying an additional 835 shares during the period. Chicago Capital LLC’s holdings in Danaher were worth $1,637,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Tsfg LLC grew its stake in shares of Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after acquiring an additional 88 shares in the last quarter. nVerses Capital LLC purchased a new stake in Danaher in the 2nd quarter valued at about $25,000. CarsonAllaria Wealth Management Ltd. bought a new position in shares of Danaher during the 2nd quarter worth approximately $25,000. Redmont Wealth Advisors LLC purchased a new position in shares of Danaher in the 1st quarter worth approximately $30,000. Finally, MFA Wealth Advisors LLC bought a new position in shares of Danaher in the second quarter valued at approximately $51,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Danaher news, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the sale, the chief executive officer now owns 97,983 shares of the company’s stock, valued at $27,435,240. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the sale, the chief executive officer now owns 97,983 shares of the company’s stock, valued at $27,435,240. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 39,659 shares of company stock worth $11,042,433. 11.10% of the stock is currently owned by insiders.

Danaher Stock Up 0.9 %

DHR stock opened at $274.38 on Friday. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70. The firm has a market capitalization of $203.23 billion, a PE ratio of 46.51, a PEG ratio of 4.49 and a beta of 0.83. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The stock has a 50-day simple moving average of $270.72 and a two-hundred day simple moving average of $260.02.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping the consensus estimate of $1.57 by $0.15. The business had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm’s revenue was down 2.9% on a year-over-year basis. During the same period in the previous year, the business earned $2.05 earnings per share. On average, equities analysts predict that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.39%. The ex-dividend date is Friday, September 27th. Danaher’s payout ratio is currently 18.31%.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on DHR shares. Wells Fargo & Company initiated coverage on Danaher in a report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price target on the stock. TD Cowen boosted their price target on shares of Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, July 24th. Barclays raised their price objective on shares of Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 24th. Bank of America boosted their target price on shares of Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Finally, Stephens assumed coverage on shares of Danaher in a report on Tuesday, October 1st. They issued an “overweight” rating and a $315.00 price target on the stock. Seven research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $282.12.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.